1 SEQUENCE LISTING

<110> Fan, Rong Kim, Nam Wolfert, Robert L. Pilkington, Glenn <120> LNG105 ANTIBODY COMPOSITIONS AND METHODS OF USE, AND USE OF LNG105 TO ASSESS LUNG CANCER RISK <130> DEX0499US.NP <140> 10/593,799 <141> 2007-08-06 <150> US 60/556,466 <151> 2004-03-25 <150> PCT/US2005/010085 <151> 2005-03-25 <160> <170> PatentIn version 3.5 <210> <211> 419 <212> PRT <213> Homo sapien <400> 1 Met Leu Gln Asn Ser Ala Val Leu Leu Val Leu Val Ile Ser Ala Ser 10 15Ala Thr Gly Ile Arg Ile Pro Leu His Arg Val Gln Pro Gly Arg Arg 20 25 30 Ile Leu Asn Leu Leu Arg Gly Trp Arg Glu Pro Ala Glu Leu Pro Lys Leu Gly Ala Pro Ser Pro Gly Asp Lys Pro Ile Phe Val Pro Leu Ser 50 60 Asn Tyr Arg Asp Val Gln Tyr Phe Gly Glu Ile Gly Leu Gly Thr Pro 65 70 75 80 Pro Gln Asn Phe Thr Val Ala Phe Asp Thr Gly Ser Ser Asn Leu Trp Val Pro Ser Arg Arg Cys His Phe Phe Ser Val Pro Cys Trp Leu His His Arg Phe Asp Pro Lys Ala Ser Ser Ser Phe Gln Ala Asn Gly Thr

Ser Ser Ala Arg Val Gly Leu Ala Arg Ala Arg Thr Arg Gly Ala Asp 385 390 395 400

Leu Gly Trp Gly Glu Thr Ala Gln Ala Gln Phe Pro Gly His His 405 410 415

His His His

<210> 2

<211> 438 <212> PRT

<213> Artificial sequence

<220>

<223> Synthetic

<400> 2

Met Leu Gln Asn Ser Ala Val Leu Leu Val Leu Val Ile Ser Ala Ser 1 10 15

Ala Thr His Glu Ala Glu Gln Ser Arg Thr Leu Ile Arg Ile Pro Leu 20 25 30

His Arg Val Gln Pro Gly Arg Arg Ile Leu Asn Leu Leu Arg Gly Trp 35 40 45

Arg Glu Pro Ala Glu Leu Pro Lys Leu Gly Ala Pro Ser Pro Gly Asp 50 55 60

Lys Pro Ile Phe Val Pro Leu Ser Asn Tyr Arg Asp Val Gln Tyr Phe 65 70 75 80

Gly Glu Ile Gly Leu Gly Thr Pro Pro Gln Asn Phe Thr Val Ala Phe 85 90 95

Asp Thr Gly Ser Ser Asn Leu Trp Val Pro Ser Arg Arg Cys His Phe 100 105 110

Phe Ser Val Pro Cys Trp Leu His His Arg Phe Asp Pro Lys Ala Ser 115 120 125

Ser Ser Phe Gln Ala Asn Gly Thr Lys Phe Ala Ile Gln Tyr Gly Thr 130 135 140

Gly Arg Val Asp Gly Ile Leu Ser Glu Asp Lys Leu Thr Ile Gly Gly 145 150 155 160

Ile Lys Gly Ala Ser Val Ile Phe Gly Glu Ala Leu Trp Glu Pro Ser 165 170 175

Leu Val Phe Ala Phe Ala His Phe Asp Gly Ile Leu Gly Leu Gly Phe 180 185 190 Pro Ile Leu Ser Val Glu Gly Val Arg Pro Pro Met Asp Val Leu Val 195 200 205 Glu Gln Gly Leu Leu Asp Lys Pro Val Phe Ser Phe Tyr Leu Asn Arg 210 215 220 Asp Pro Glu Glu Pro Asp Gly Gly Glu Leu Val Leu Gly Gly Ser Asp 225 235 240 Pro Ala His Tyr Ile Pro Pro Leu Thr Phe Val Pro Val Thr Val Pro 245 250 255 Ala Tyr Trp Gln Ile Arg Met Glu Arg Val Lys Val Gly Pro Gly Leu 260 265 270 Thr Leu Cys Ala Lys Gly Cys Ala Ala Ile Leu Asp Thr Gly Thr Ser 280 285 Leu Ile Thr Gly Pro Thr Glu Glu Ile Arg Ala Leu His Ala Ala Ile 290 295 300 Gly Gly Ile Pro Leu Leu Thr Gly Glu Tyr Ile Ile Leu Cys Ser Glu 305 310 315 320Ile Pro Lys Leu Pro Ala Val Ser Phe Leu Leu Gly Gly Val Trp Phe 325 330 335 Asn Leu Thr Ala His Asp Tyr Val Ile Gln Thr Thr Arg Asn Gly Val 340 350 Arg Leu Cys Leu Ser Gly Phe Gln Ala Leu Asp Val Pro Pro Pro Ala 355 360 365 Gly Pro Phe Trp Ile Leu Gly Asp Val Phe Leu Gly Thr Tyr Val Ala 370 380 Val Phe Asp Arg Gly Asp Met Lys Ser Ser Ala Arg Val Gly Leu Ala 385 390 395 400 Arg Ala Arg Thr Arg Gly Ala Asp Leu Gly Trp Gly Glu Thr Ala Gln
405 410 415 Ala Gln Phe Pro Gly Ala Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala 420 425 430

```
His His His His His 435
```

- <210> 3 <211> 4 <212> PRT <213> Artificial sequence
- <220> <223> Synthetic
- <400> 3
- Ser Arg Thr Leu 1

- <210> 4 <211> 11 <212> PRT <213> Artificial sequence
- <220> <223> Synthetic
- <400> 4

Ala Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala 1 5 10